New combo therapy offers hope for patients with stubborn lymphoma
NCT ID NCT07077512
First seen Jan 22, 2026 · Last updated May 23, 2026 · Updated 14 times
Summary
This study tests a combination of two treatments—an immune cell therapy (relmacabtagene autoleucel) and an immunotherapy drug (sintilimab)—in 30 adults with relapsed or refractory B-cell lymphoma (including diffuse large B-cell, mantle cell, and follicular lymphoma). The goal is to see if the combination improves the chance of complete remission at 3 months. Participants must be between 18 and 70 years old and have CD19-positive tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA ( FL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fifth Affiliated Hospital of Guangzhou Medical University
NOT_YET_RECRUITINGGuangzhou, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Guangzhou overseas Chinese hospital
NOT_YET_RECRUITINGGuangzhou, 510632, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sun Yat-sen Universitiy Cancer Center
RECRUITINGGuangzhou, 51000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.